Do P - Search Results

1

Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.

Houdu B, Lasnon C, Licaj I, Thomas G, Do P, Guizard AV, Desmonts C, Aide N. Houdu B, et al. Among authors: do p. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):421-428. doi: 10.1007/s00259-018-4151-8. Epub 2018 Sep 14. Eur J Nucl Med Mol Imaging. 2019. PMID: 30218317

2

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.

Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, Aide N. Lasnon C, et al. Among authors: do p. Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):985-96. doi: 10.1007/s00259-013-2391-1. Epub 2013 Apr 6. Eur J Nucl Med Mol Imaging. 2013. PMID: 23564036 Free PMC article. Clinical Trial.

3

¹⁸F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.

Lasnon C, Majdoub M, Lavigne B, Do P, Madelaine J, Visvikis D, Hatt M, Aide N. Lasnon C, et al. Among authors: do p. Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2324-2335. doi: 10.1007/s00259-016-3441-2. Epub 2016 Jun 21. Eur J Nucl Med Mol Imaging. 2016. PMID: 27325312 Free article.

4

Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.

Lasnon C, Salomon T, Desmonts C, Dô P, Oulkhouir Y, Madelaine J, Aide N. Lasnon C, et al. Among authors: do p. Ann Nucl Med. 2017 Feb;31(2):125-134. doi: 10.1007/s12149-016-1135-2. Epub 2016 Nov 3. Ann Nucl Med. 2017. PMID: 27812791

5

Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.

Houdu B, Lasnon C, Licaj I, Thomas G, Do P, Guizard AV, Desmonts C, Aide N. Houdu B, et al. Among authors: do p. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):533-534. doi: 10.1007/s00259-018-4216-8. Eur J Nucl Med Mol Imaging. 2019. PMID: 30535744

6

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer.

Dumont D, Dô P, Lerouge D, Planchard G, Riffet M, Dubos-Arvis C, Danhier S, Gervais R. Dumont D, et al. Among authors: do p. Am J Case Rep. 2017 Aug 15;18:890-893. doi: 10.12659/ajcr.903528. Am J Case Rep. 2017. PMID: 28808224 Free PMC article.

7

Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.

Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Dô P, Dubos-Arvis C, Chouaïd C, Gervais R. Lesueur P, et al. Among authors: do p. Cancer Med. 2018 Nov;7(11):5505-5513. doi: 10.1002/cam4.1825. Epub 2018 Oct 11. Cancer Med. 2018. PMID: 30311424 Free PMC article.

8

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C. Descourt R, et al. Among authors: do p. Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14. Lung Cancer. 2019. PMID: 31491676 Free article.

9

Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.

Johnson AC, Dô P, Richard N, Dubos C, Michels JJ, Bonneau J, Gervais R. Johnson AC, et al. Among authors: do p. Lung Cancer. 2016 Sep;99:38-40. doi: 10.1016/j.lungcan.2016.06.010. Epub 2016 Jun 14. Lung Cancer. 2016. PMID: 27565911

10

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. Gandhi L, et al. Among authors: do p. Eur J Cancer. 2017 Sep;82:27-33. doi: 10.1016/j.ejca.2017.05.019. Epub 2017 Jul 10. Eur J Cancer. 2017. PMID: 28646771 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

269 results

Search Page